Drugs Made In America Acquisition Corp. closes $200M IPO and $4M private placement

Drugs Made In America Acquisition Corp.

IPO of 20,000,000 units at $10.00 each raises $200,000,000 gross proceeds.
Sponsor purchased 400,000 private units for $4,000,000; $1,100,000 receivable noted.
Net proceeds of $201,000,000 deposited into trust account ($10.05 per public share).
Balance sheet shows $201M in trust, $6M deferred underwriting fees, and shareholders' deficit of $6.6M.
Going concern warning: working capital deficit of $555,420; company must complete a business combination within 15-21 months or liquidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.